The company's platform creates drug microparticles large enough for tumor retention but with a massive surface area for sustained drug release. This is counterintuitive to typical engineering, where surface area is increased by making particles smaller, and it forms the basis of their intellectual property.

With digital twins for drug testing and local 3D printing of drugs, pharma's role could shift from mass manufacturing to licensing molecule formulas. A doctor would test a drug on a digital twin and a pharmacy would print the personalized dose on site.

Eupraxia's technology is defined by its precision: delivering a stable, flat dose directly into target tissue for up to a year. This hyper-local approach mimics the stability of a continuous IV infusion, aiming to maximize efficacy while minimizing systemic side effects caused by the 'peaks and troughs' of conventional pills or injections.

Varda Space, an in-orbit manufacturing company, simplifies its business model by treating space launches as a mere shipping cost, not a core competency. Co-founder Will Bruey notes they use SpaceX instead of FedEx, but from a business perspective, 'shipping is shipping.' This focus allows them to concentrate on their true value: manufacturing in microgravity.

Varda manufactures products like pharmaceuticals and fiber optics in space, where zero gravity acts as an "off switch" enabling unique molecular structures. Their key advantage is the difficult-to-replicate capability of returning materials safely from orbit.

Unlike power-hungry data center satellites that require a specific sun-synchronous orbit, Varda's manufacturing satellites are orbit-agnostic. This operational flexibility allows them to use a wider variety of rocket launches, including less crowded and potentially cheaper missions, creating a key competitive advantage.

By injecting gene therapy directly into the heart, Medera bypasses systemic circulation. This allows for a 100x lower dose than traditional IV methods, which eliminates the need for immunosuppressants, reduces severe adverse events, and significantly lowers manufacturing costs, making gene therapy for common diseases commercially viable.

A mass driver on the moon is not just for deep space missions. Varda's Delian Asparouhov explains it would be a game-changer for Low Earth Orbit (LEO) manufacturing by enabling the free delivery of basic materials like water from the moon. This would drastically reduce the cost and complexity of orbital factories that currently must launch all inputs from Earth.

AeroRx's core innovation is a new delivery system for existing drugs. While five dual-bronchodilators are available in handheld inhalers, none exist for nebulization. This targets older, sicker COPD patients who cannot use inhalers effectively, proving value can be created by improving *how* a drug is administered rather than discovering a new active ingredient.